1. What immediate action your company has taken or intends to take to evaluate and respond to the implications of the mobilization decree?

The safety and security of our people remains our number one objective. As such, upon the announcement of the partial mobilization decree on the territory of the Russian Federation we conducted a comprehensive mapping of all our local associates, with an enhanced focus on those with previous exposure and experience with the military. For those with a high likelihood of being mobilized, we are conducting routine welfare checks. We continue to closely monitor the situation and changes in the regulatory environment. Also, as a medicines company, Novartis's priority is to ensure that our life-changing medicines remain available to patients. Within our manufacturing and distribution networks (both globally and locally) the appropriate business continuity measures have been activated to ensure that those in need continue to get the best possible support from Novartis.

2. If your company chooses to continue operating in Russia despite the declared partial mobilization, how are you planning to mitigate the heightened risk of contributing or being directly linked to the armed conflict and exacerbating the situation?

Our immediate priority is to protect the safety and security of our people, while providing access to medicines to people who need them, no matter where they are. We continue to closely monitor the situation and changes in the regulatory environment. At the same time, we are offering multiple legal and human rights resources for our associates to support them. Additional resources related to job security and financial support are available should our associates require any.